Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

NCT01077336 | Completed

• 1 other identifier: G098881
• Study Type: observational
• Target: 450
• Locations: 0 countries
• Sites: N/A

Brief Summary

Susceptibility testing is commonly employed in patients with bacterial infections in order to guide rational use of antibiotics; however, the use of antifungal susceptibility testing is limited due to lack of availability, costs, and delays in receiving results. The goals of antifungal susceptibility testing should mirror those of antibacterial susceptibility testing: to predict clinical response or failure. Additionally, susceptibility reports should be used as a guide for physicians when transitioning patients from parenteral to oral antifungal agents. Currently, it is unknown whether antifungal susceptibility testing impacts treatment decisions in hospitals that routinely perform Candida susceptibility testing. The purpose of this study is to evaluate the changes in antifungal treatment based on in vitro susceptibility reports and how these decisions affect mortality, recurrence of infection, and length of hospital stay in candidemia patients.

Conditions

Blood Stream Infections; Candida

Keywords

susceptibility testing

Outcome Measures

Primary Outcomes (1)

• Assess empiric choice of antifungal therapy in hospitalized patients with candidemia.

  Assessments made for 30-days after postivie blood culture

Study Arms (1)

Hospitalized patients with candidemia

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This will be a retrospective cohort study of 400 hospitalized patients with bloodstream infections from January 2006 to January 2009 due to Candida species

You may qualify if:

• Hospitalized patients with bloodstream infections due to Candida species

You may not qualify if:

• Patients will be excluded from this study if their medical charts contain incomplete outcome or susceptibility data. Patients treated empirically or definitively with amphotericin-based products will also be excluded

Sponsors & Collaborators

• University of Houston: lead
• Merck Sharp & Dohme LLC: collaborator

MeSH Terms

Conditions

Torulopsis

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor and Chair

Study Record Dates

• First Submitted: February 25, 2010
• First Posted: March 1, 2010
• Study Start: January 1, 2010
• Primary Completion: January 1, 2011
• Study Completion: January 1, 2011
• Last Updated: July 16, 2014

Record last verified: 2014-07